Literature DB >> 4054706

Morbidity and mortality after peritoneovenous shunt surgery for refractory ascites.

D Rubinstein, I McInnes, F Dudley.   

Abstract

A prospective analysis of the morbidity and mortality after peritoneovenous shunting was carried out in 25 patients who had a total of 27 shunts for refractory ascites. Major complications were limited to the patients in whom ascites was secondary to hepatic rather than peritoneal disease. Immediate postoperative complications followed 17 out of the 23 shunts carried out in patients with liver disease and included septicaemia (two), profound hypotension (two), pulmonary oedema (one), and clinically evident disseminated intravascular coagulation (14). Long term morbidity was again limited to the patients with liver disease and included chronic shunt infection (two) and major venous thrombosis (two). Shunt associated mortality was only seen in the patients with liver disease. Despite late shunt blockage in five long term survivors with alcoholic liver disease fluid retention was easily controlled by simple medical means probably because of improved liver function associated with abstinence from alcohol. It is concluded that: (1) patients with hepatic and malignant ascites respond differently to the insertion of a peritoneovenous shunt; (2) Shunt patency should be monitored regularly in patients with liver disease and, because of the potential for septic and thrombotic complications, if blocked the shunt should be removed and; (3) because of the morbidity and mortality of peritoneovenous shunt surgery in patients with liver disease and refractory ascites, an alternative mode of therapy, such as repeated ultrafiltration and reinfusion of ascitic fluid, may be a more effective initial therapeutic approach especially in patients in whom there is a reversible element to their underlying liver disease.

Entities:  

Mesh:

Year:  1985        PMID: 4054706      PMCID: PMC1432938          DOI: 10.1136/gut.26.10.1070

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Treatment of ascites by reinfusion of concentrated peritoneal fluid--review of 318 procedures in 210 patients.

Authors:  V G Lévy; P Opolon; N Pauleau; J Caroli
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

2.  Further experience with peritoneo-venous shunt for ascites.

Authors:  H H LeVeen; S Wapnick; S Grosberg; M J Kinney
Journal:  Ann Surg       Date:  1976-11       Impact factor: 12.969

3.  Nephrotic syndrome associated with bacteraemia after shunt operations for hydrocephalus.

Authors:  J A Black; D N Challacombe; B G Ockenden
Journal:  Lancet       Date:  1965-11-06       Impact factor: 79.321

4.  LaVeen continuous peritoneal-jugular shunt. Improvement of renal function in ascitic patients.

Authors:  S Wapnick; S Grosberg; M Kinney; H H LeVeen
Journal:  JAMA       Date:  1977-01-10       Impact factor: 56.272

5.  Peritoneovenous shunts in the management of malignant ascites.

Authors:  R G Souter; D Tarin; M G Kettlewell
Journal:  Br J Surg       Date:  1983-08       Impact factor: 6.939

6.  Coagulopathy of peritoneovenous shunts: studies on the pathogenic role of ascitic fluid collagen and value of antiplatelet therapy.

Authors:  H H Salem; F J Dudley; A Merrett; J Perkin; B G Firkin
Journal:  Gut       Date:  1983-05       Impact factor: 23.059

7.  The aggregation of human platelets by ascitic fluid: a possible mechanism for disseminated intravascular coagulation complicating LeVeen shunts.

Authors:  H H Salem; J Koutts; C Handley; M B van Der Weyden; F J Dudley; B G Firkin
Journal:  Am J Hematol       Date:  1981-09       Impact factor: 10.047

8.  Management of malignant ascites with peritoneovenous shunting.

Authors:  R B Reinhold; J J Lokich; J Tomashefski; P Costello
Journal:  Am J Surg       Date:  1983-04       Impact factor: 2.565

9.  Peritonitis in cirrhotic patients with LeVeen shunts.

Authors:  G P Wormser; R C Hubbard
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

10.  Renal lesions of subacute infective endocarditis.

Authors:  J M Boulton-Jones; J G Sissons; D J Evans; D K Peters
Journal:  Br Med J       Date:  1974-04-06
View more
  8 in total

1.  Chylous ascites following liver resection--case report.

Authors:  K Prabhakaran; Mali Vidyadhar; Patankar Jahoorahmad; Tan Hwee Neo Grace
Journal:  Pediatr Surg Int       Date:  2004-10-27       Impact factor: 1.827

2.  Peritoneovenous shunt after failure of octreotide treatment for chylous ascites in lymphangioleiomyomatosis.

Authors:  Laurent Lefrou; Louis d'Alteroche; Yahia Harchaoui; Dominique Franco; Etienne Henry Metman
Journal:  Dig Dis Sci       Date:  2007-07-20       Impact factor: 3.199

Review 3.  [Peritoneovenous shunt in the treatment of therapy-refractory ascites].

Authors:  C A Eriksen; A Cuschieri
Journal:  Langenbecks Arch Chir       Date:  1988

4.  Concentrated ascitic fluid reinfusion after cascade filtration in tense ascites.

Authors:  L Rossaro; A Graziotto; S Bonato; M Plebani; D H van Thiel; A Burlina; R Naccarato; M Salvagnini
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

Review 5.  Symptomatic Fluid Drainage: Peritoneovenous Shunt Placement.

Authors:  Hooman Yarmohammadi; George I Getrajdman
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

6.  Peritoneovenous shunts for palliation of the patient with malignant ascites.

Authors:  D L Schumacher; T J Saclarides; E D Staren
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

7.  Treatment of Chylous Ascites with Peritoneovenous Shunt (Denver Shunt) following Retroperitoneal Lymph Node Dissection in Patients with Urological Malignancies: Update of Efficacy and Predictors of Complications.

Authors:  Hooman Yarmohammadi; Juliana Schilsky; Jeremy C Durack; Lynn A Brody; Ulrika Asenbaum; Sara Velayati; Ernesto Santos; Adrian J Gonzalez-Aguirre; Joseph P Erinjeri; Nadia Petre; Stephen B Solomon; Joel Sheinfeld; George I Getrajdman
Journal:  J Urol       Date:  2020-05-05       Impact factor: 7.600

Review 8.  Chylous Ascites: Evaluation and Management.

Authors:  Said A Al-Busafi; Peter Ghali; Marc Deschênes; Philip Wong
Journal:  ISRN Hepatol       Date:  2014-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.